论文部分内容阅读
目的探讨植入用5Fu缓释剂局部埋植化疗用于治疗卵巢癌腹膜后转移的可行性。方法建立卵巢癌腹膜后转移动物模型,随机分成三组,腹膜后局部埋植组(A组)埋植5Fu缓释剂2mg,腹腔给药组(B组)注射同等剂量的氟尿嘧啶针剂,空白对照组(C组)腹腔注射生理盐水,观察肿瘤的生物学行为和治疗效果。结果A组较B、C组瘤体积明显减小,重量减轻,荷瘤鼠生存状态提高。结论腹膜后局部埋植5Fu缓释剂对卵巢癌腹膜后转移具有明显的治疗效果,为临床治疗卵巢癌腹膜后转移提供了一种新的治疗方法。
Objective To investigate the feasibility of locally implanted chemotherapy with 5Fu sustained-release agent for the treatment of retroperitoneal metastasis of ovarian cancer. Methods The animal model of retroperitoneal metastasis of ovarian cancer was established and randomly divided into three groups. The rats in the retroperitoneal implantation group (group A) were implanted with 2 mg 5Fu sustained-release agent and the intraperitoneal injection group (group B) with the same dose of fluorouracil injection. Group C (Group C) was injected intraperitoneally with normal saline to observe the biological behavior and therapeutic effect of the tumor. Results The volume of tumor in group A was significantly lower than that in group B and C, the weight was reduced, and the survival of tumor-bearing mice was improved. Conclusion The retroperitoneal implantation of 5Fu sustained-release agent has a significant therapeutic effect on retroperitoneal metastasis of ovarian cancer and provides a new treatment for the clinical treatment of retroperitoneal metastasis of ovarian cancer.